Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-05-25

Clinical Trial Update: A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 trial comparing LY2963016 to Lantus in adult Chinese participants with type 2 diabetes completed; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LY2963016 (insulin glargine)
  • Lantus (insulin glargine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2021-05-25